Please login to the form below

Not currently logged in
Email:
Password:

Merz Pharma appoints William Humphries as US CEO

He joins from GlaxoSmithKline company Stiefel

Merz Pharma Group has appointed a new leader for its North American business, selecting the former president of GlaxoSmithKline's Stiefel unit William Humphries.

As CEO of Merz's US business, Humphries will be based in Greensboro, North Carolina and takes charge of the company's medical dermatology global business unit.

He will also oversee the strategic direction of three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics and Merz Pharma Canada.

Merz Pharmaceuticals GmbH's CEO Dr Martin Zugel said: "Few people can match Bill's extensive knowledge across the pharmaceutical and aesthetic medicine categories. His knowledge, combined with his unparalleled experience as an innovative driver of organic and acquired expansion, brings a new era of leadership to the Merz companies.

"We are confident that Bill will lead our companies into a period of accelerated growth in the North American market."

Prior to joining Merz, Humphries served as president of Stiefel, during which time he spearheaded two major acquisitions and led the global integration of Stiefel into GlaxoSmithKline.

Before joining Stiefel, Humphries held a number of senior executive roles within Allergan, concluding as vicepresident of the US skincare business.

Humphries' appointment adds to a number of senior executive hires at Merz, including head of global business unit OTC/OTX and emerging markets Hans Regenauer and head of global business unit ethical pharma and regional head Western Europe Stefan Brinkmann.

15th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics